A novel approach to safer glucocorticoid receptor–targeted anti-lymphoma therapy via REDD1 (regulated in development and DNA damage 1) inhibition
Lesovaya E.A.,
Savinkova A.V.,
Morozova O.V.,
Lylova E.S.,
Zhidkova E.M.,
Kirsanov K.I.,
Yakubovskaya M.G.,
Kulikov E.P.,
Klopot A.,
Baida G.,
Budunova I.,
Gordon L.I.,
Readhead B.,
Dudley J.T.
Связанные документы (рекомендация CORE)